
Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this gap will narrow in favor of Merck.
Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this gap will narrow in favor of Merck.